A phase II, open-label trial of bortezomib (VELCADEĀ®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
Crossref DOI link: https://doi.org/10.1007/s00280-016-2997-7
Published Online: 2016-03-19
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kontopodis, E.
Kotsakis, A.
Kentepozidis, N.
Syrigos, K.
Ziras, N.
Moutsos, M.
Filippa, G.
Mala, A.
Vamvakas, L.
Mavroudis, D.
Georgoulias, V.
Agelaki, S.
Text and Data Mining valid from 2016-03-19